

MATERIAL CHANGE REPORT

1. Name and Address of Company:

Critical Outcome Technologies Inc.
700 Collip Circle, Suite 213
London, Ontario N6G 4X8

2. Date of Material Change:

May 1, 2008

3. News Release:

A press release disclosing the details outlined in this Material Change Report was issued by Critical Outcome Technologies Inc. ("COTI") from London, Ontario on May 2, 2008 and disseminated through the facilities of Marketwire.

4. Summary of Material Change:

COTI announced its amalgamation with 6441513 Canada Inc., a wholly owned subsidiary of COTI, pursuant to the Business Corporations Act (Ontario).

5. Full Description of Material Change:

Please see the attached press release.

6. Reliance on Confidentiality Section of the Act:

Not applicable.

7. Omitted Information:

Not applicable.

8. Executive Officer:

Further information regarding the matters described in this report may be obtained from Gene Kelly, Chief Financial Officer. Mr. Kelly is knowledgeable about the details of the material change and may be contacted at (519) 858-5157.

DATED May 2, 2008, at London, Ontario.



Press Release

FOR IMMEDIATE RELEASE

CRITICAL OUTCOME TECHNOLOGIES INC. ANNOUNCES AMALGAMATION WITH DDP THERAPEUTICS

London, Ontario (May 2, 2008): Critical Outcome Technologies Inc. (TSX Venture: COT) announced today that it has amalgamated with its wholly owned subsidiary, 6441513 Canada Inc, operating as DDP Therapeutics (DDP) effective May 1, 2008. DDP was acquired as announced on November 27, 2007. This amalgamation completes the process of integrating the small cell lung cancer (SCLC) molecule library of DDP with the research development operations of Critical Outcome Technologies Inc. (COTI).

Since acquisition COTI has added significant value to the SCLC library as part of its commercialization strategy for these small molecules with emphasis on the lead compound COTI-2. In this regard, the data package for COTI-2 has been bolstered with a stronger understanding of the compound's mechanism of action.

COTI has also advanced other candidates in the SCLC library into preclinical development. COTI-4 and COTI-58 will enter into synthesis in June 2008. COTI-219 is expected to undergo mechanism of action experiments in July 2008.

"I am pleased to report positive developments in our oncology program as a result of the acquisition of DDP," said Dr. Wayne Danter, President and Chief Scientific Officer of COTI. "The ongoing development and progress of our oncology drug candidates has helped build a robust pipeline for COTI and augments our business development opportunities."

About Critical Outcome Technologies Inc.

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

For further information, visit the website at www.criticaloutcome.com or contact:

Dr. Wayne Danter, President & CSO
519-858-5157
wdanter@criticaloutcome.com

Gene Kelly, CFO
519-858-5157
gkelly@criticaloutcome.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.